- $102.63m
- $56.66m
- $28.70m
- 26
- 24
- 50
- 24
Annual income statement for Vaxart, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 4.05 | 0.892 | 0.107 | 7.38 | 28.7 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 34.2 | 69.9 | 108 | 90.7 | 95 |
| Operating Profit | -30.2 | -69 | -108 | -83.3 | -66.3 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -32 | -70.4 | -108 | -82.2 | -66.7 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -32.2 | -70.5 | -108 | -82.5 | -66.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -32.2 | -70.5 | -108 | -82.5 | -66.9 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -32.2 | -70.5 | -108 | -82.5 | -66.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.371 | -0.584 | -0.858 | -0.569 | -0.331 |